We’re thrilled to welcome Ashley Lakner, PhD, our new Chief Scientific Officer (CSO)!
Ashley joins our team with an exceptional track record in oncology drug discovery and precision medicine. Most recently leading Oncology Discovery at Roche pRED, and previously as VP of Precision Molecular Oncology at Bayer, Ashley advanced multiple molecules across key modalities into early clinical development through rigorous translational research.
Ashley brings deep scientific expertise, extensive drug discovery experience and proven leadership of multidisciplinary teams, helping us advance our mission of turning breakthrough biology into meaningful patient impact.
Welcome to the team!
Ashley Lakner, Cure51's Chief Scientific Officer (CSO)
Updated: April 1, 2026
